Intercept Pharma (ICPT) Misses Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts ICPT Hot Sheet
Join SI Premium – FREE
Intercept Pharma (NASDAQ: ICPT) reported Q2 EPS of ($1.99), $0.04 worse than the analyst estimate of ($1.95). Revenue for the quarter came in at $445 thousand versus the consensus estimate of $2.17 million.
For earnings history and earnings-related data on Intercept Pharma (ICPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- VNET Group (VNET) Misses Q2 EPS by 164c
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Goldman Sachs updates view on protein markets ahead of earnings
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
